Business Wire

CITY-OF-ESPOO

31.5.2022 08:02:12 CEST | Business Wire | Press release

Share
Annual Eurocities Conference Held by Espoo Focuses on Cities’ Climate Leadership

At the three-day conference that brings the management of European cities together, the topics discussed include the inclusion of young people, co-creation and cities’ leadership in the work against climate change. The theme of the annual conference, An Era of New Beginnings, consists of three parts, Dream, Act and Lead, through which these topics are studied. The conference attendees include city leadership from Oslo, Rotterdam, Helsinki, Brussels, Stockholm and Munich, among other cities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005019/en/

On Friday, one of the keynote speakers will be Executive Vice-President of the European Commission Frans Timmermans , who will introduce the discussion on climate-neutral cities.

“Cities play a key role in the progress towards the EU’s climate goals and building a sustainable future. The annual conference also strengthens the dialogue between cities and the European Commission. However, achieving the goals will be impossible if cities cannot extensively involve operators from all sectors of society. Co-creation and cooperation between the public and private sector are some of the overarching themes of the conference, in addition to climate leadership and young people’s inclusion,” says Milla Ovaska , Head of International Affairs at the City of Espoo.

As a part of the conference and the European Year of Youth, Espoo is organising the Future Mentors programme in which young people living in European cities engage in dialogue with the policymakers of their cities. This is called reverse mentoring.

“We wanted to provide young people with an opportunity to voice their dreams, wishes and concerns about the future of their home city. The decisions that we are making now will have long-term influence, and young people will be the ones living in the future we create. We would like the programme to encourage policymakers to engage in dialogue and give space to new ways of thinking,” says Marianne Julkunen , Partnership Coordinator.

Eurocities Awards to best practices of resident inclusion

On the evening of Thursday 9 June, the conference programme includes the Eurocities Awards ceremony , which showcases the member cities’ projects that have succeeded best in involving their residents and influencing their quality of life. This year’s awards will be given in three categories: ‘Future generations transforming the cities,’ ‘Skills and competences for the future’ and ‘Scalable solutions for positive climate impact.’ The winners will be selected by a five-person jury.

Representatives of the media are cordially invited to attend the annual Eurocities conference on-site at Espoo, Finland. The conference is also available virtually on its website .

#Eurocities2022
#FutureMentors2022

The conference has been created in collaboration with various organisations, all relevant to building future-proof cities and societies. The main partners are Aalto University and VTT. You can find all partners at: eurocities2022.eu/partners .

Eurocities is the key network of European cities for Espoo. Eurocities supervises interests at the level of the EU, generates information about the EU’s funding application rounds and EU legislation, and functions as a peer learning platform for its member cities.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye